BD-211

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameBD-211
Drug Alias NameAutologous CD34+Stem Cells with a Lentiviral Vector coding βA-T87Q-GlobinBD-211
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionHemoglobin beta chain stimulantsGene transference
TargetsHemoglobin beta chain
Therapy Area/Indicationsbeta-ThalassemiaHematologic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai BDgene Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai BDgene Co Ltd
Inactive CompaniesN/A
Active Indicationsbeta-ThalassemiaHematologic Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A